HUP0302306A2 - Propionic acid derivatives with ppar-alpha activating properties - Google Patents
Propionic acid derivatives with ppar-alpha activating propertiesInfo
- Publication number
- HUP0302306A2 HUP0302306A2 HU0302306A HUP0302306A HUP0302306A2 HU P0302306 A2 HUP0302306 A2 HU P0302306A2 HU 0302306 A HU0302306 A HU 0302306A HU P0302306 A HUP0302306 A HU P0302306A HU P0302306 A2 HUP0302306 A2 HU P0302306A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- hydrogen atom
- atom
- alkyl
- compounds
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title abstract 2
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 title 1
- 150000005599 propionic acid derivatives Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 229910052785 arsenic Inorganic materials 0.000 abstract 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
A találmány tárgyát képezik olyan (I) általános képletű potenciálisanPPAR-alfa aktiváló vegyületek, ahol a képletben A jelentése -CH2- vagy-CH2CH2-csoport, X jelentése O, S vagy CH2-csoport, R1, R2 és R3azonos vagy különböző, és jelentése egymástól függetlenülhidrogénatom, 1-6 szénatomos alkil-, 3-7 szénatomos cikloalkil-,hidroxi-, 1-6 szénatomos alkoxi-, 6-10 szénatomos ariloxicsoport,halogénatom, trifluormetil-, trifluormetoxi-, 1-6 szénatomos alkil-aminoszulfonil-, nitro- vagy cianocsoport, vagy R1 és R2 kétszomszédos szénatomhoz kötődik, és ezekkel együtt anellált ciklohexán-vagy benzolgyűrűt alkot, ahol ez utóbbi adott esetben szubsztituált,R4 jelentése hidrogénatom vagy 1-4 szénatomos alkilcsoport, R5 és R6jelentése hidrogénatom vagy azzal a szénatommal együtt, amelyhezkötődnek, karbonilcsoport, R7 jelentése hidrogénatom, 1-6 szénatomosalkil-, fenil- vagy benzilcsoport, ahol az aromás csoportokegyszeresen, kétszeresen vagy háromszorosan azonos vagy különbözőcsoportokkal lehetnek szubsztituálva, R8 jelentése hidrogénatom, 6-10szénatomos aril- vagy 1-4 szénatomos alkilcsoport, amely lehethelyettesítve, R9 és R10 azonos vagy különböző, és jelentése egymástólfüggetlenül hidrogénatom, 1-6 szénatomos alkil-, 1-6 szénatomosalkoxi-, trifluormetil-, trifluormetoxicsoport vagy halogénatom, R11és R12 azonos vagy különböző, és jelentése egymástól függetlenülhidrogénatom vagy 1-6 szénatomos alkilcsoport, vagy azzal aszénatommal együtt, amelyhez kötődnek, 4-7 szénatomos ciklo-alkilcsoport, és R13 jelentése hidrogénatom vagy hidrolizálhatócsoport, amely a megfelelő karbonsavvá alakítható át, valamint ezekgyógyászatilag elfogadható sói, hidrátjai és szolvátjai. Ezek avegyületek potenciálisan koronáris szívbetegségek kezelésérealkalmazhatók. A találmány további tárgyát képezi eljárás a fentivegyületek előállítására, a vegyületek alkalmazása gyógyszerkészítményelőállítására, a vegyületek alkalmazása betegségek kezelésére;valamint ezeket a hatóanyagokat tartalmazó gyógyszerkészítmény, amelya hatóanyagon kívül inert, nemtoxikus, gyógyászatilag elfogadhatóhordozóanyagokat, segédanyagokat, oldószereket, vivőanyagokat,emulgeátorokat és/vagy diszpergálószereket tartalmaz. ÓThe subject of the invention are potentially PPAR-alpha activating compounds of the general formula (I), where in the formula A is -CH2- or -CH2CH2-group, X is O, S or CH2-group, R1, R2 and R3 are the same or different, and independently hydrogen atom, C1-6 alkyl, C3-7 cycloalkyl, hydroxy, C1-6 alkoxy, C6-10 aryloxy, halogen atom, trifluoromethyl, trifluoromethoxy, C1-6 alkylaminosulfonyl, nitro or cyano group, or R1 and R2 are attached to two neighboring carbon atoms and together with them form an fused cyclohexane or benzene ring, where the latter is optionally substituted, R4 is a hydrogen atom or an alkyl group with 1-4 carbon atoms, R5 and R6 are a hydrogen atom or together with that carbon atom, to which they are attached, a carbonyl group, R7 is a hydrogen atom, a 1-6 carbon atom alkyl, phenyl or benzyl group, where the aromatic groups can be mono, doubly or triply substituted with the same or different groups, R8 is a hydrogen atom, a 6-10 carbon atom aryl or a 1-4 carbon atom alkyl group, which may be substituted, R9 and R10 are the same or different and are independently a hydrogen atom, a C1-6 alkyl, a C1-6 alkoxy, trifluoromethyl, trifluoromethoxy group or a halogen atom, R11 and R12 are the same or different and are independently a hydrogen atom or a C1-6 alkyl group , or together with the arsenic atom to which they are attached, a cycloalkyl group having 4 to 7 carbon atoms, and R13 is a hydrogen atom or a hydrolyzable group which can be converted into the corresponding carboxylic acid, as well as their pharmaceutically acceptable salts, hydrates and solvates. These compounds can potentially be used to treat coronary heart disease. A further subject of the invention is a process for the production of the above compounds, the use of the compounds for the production of pharmaceutical preparations, the use of the compounds for the treatment of diseases, as well as a pharmaceutical preparation containing these active ingredients, which, in addition to the active ingredient, contains inert, non-toxic, medically acceptable carriers, excipients, solvents, carriers, emulsifiers and/or dispersants . HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10049208 | 2000-10-05 | ||
| DE10124905A DE10124905A1 (en) | 2000-10-05 | 2001-05-22 | propionic acid derivatives |
| PCT/EP2001/011005 WO2002028821A2 (en) | 2000-10-05 | 2001-09-24 | Propionic acid derivatives with ppar-alpha activating properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302306A2 true HUP0302306A2 (en) | 2003-10-28 |
| HUP0302306A3 HUP0302306A3 (en) | 2005-02-28 |
Family
ID=26007267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302306A HUP0302306A3 (en) | 2000-10-05 | 2001-09-24 | Propionic acid derivatives with ppar-alpha activating properties |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1328508A2 (en) |
| JP (1) | JP2004510757A (en) |
| CN (1) | CN1479716A (en) |
| AU (1) | AU2001293838A1 (en) |
| BG (1) | BG107684A (en) |
| BR (1) | BR0114437A (en) |
| CA (1) | CA2424540A1 (en) |
| CZ (1) | CZ2003964A3 (en) |
| EE (1) | EE200300140A (en) |
| HN (1) | HN2001000223A (en) |
| HR (1) | HRP20030346A2 (en) |
| HU (1) | HUP0302306A3 (en) |
| IL (1) | IL155125A0 (en) |
| MA (1) | MA25917A1 (en) |
| MX (1) | MXPA03002901A (en) |
| NO (1) | NO20031517L (en) |
| NZ (1) | NZ525119A (en) |
| PL (1) | PL361162A1 (en) |
| RU (1) | RU2003112968A (en) |
| SK (1) | SK4132003A3 (en) |
| UY (1) | UY26951A1 (en) |
| WO (1) | WO2002028821A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10151390A1 (en) * | 2001-10-18 | 2003-05-08 | Bayer Ag | acetic acid derivatives |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| WO2004037778A1 (en) * | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes |
| EA200500517A1 (en) * | 2002-10-21 | 2005-10-27 | Янссен Фармацевтика Н. В. | TREATMENT OF SYNDROME X BY SUBSTITUTE TETRALINES AND INDANDS |
| DE60327543D1 (en) * | 2002-10-21 | 2009-06-18 | Janssen Pharmaceutica Nv | SUBSTITUTED TETRALINE AND INDANE AND ITS USE |
| WO2004063184A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Thiophene derivative ppar modulators |
| CA2824106A1 (en) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| AR048931A1 (en) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | PROCESS FOR THE PREPARATION OF SUBSTITUTED AND INDIAN TETRALIN DERIVATIVES AND PREPARATION OF SYNTHESIS INTERMEDIARIES |
| CN100344618C (en) * | 2004-05-24 | 2007-10-24 | 北京摩力克科技有限公司 | N-benzyl acryloyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist |
| KR100699928B1 (en) | 2004-10-05 | 2007-03-26 | 재단법인서울대학교산학협력재단 | Process for preparing the intermediate compounds for ppar ? ligands |
| ES2519346T3 (en) | 2004-12-13 | 2014-11-06 | Ono Pharmaceutical Co., Ltd. | Azetidinecarboxylic acid derivative and medicinal use thereof |
| CN101054372B (en) * | 2006-04-11 | 2010-10-13 | 中国科学院上海药物研究所 | Pyrimidine substituted benzenepropanoic acid derivative, its preparation method and use in curing polycystic kidney disease |
| JP5357894B2 (en) | 2008-12-01 | 2013-12-04 | 田辺三菱製薬株式会社 | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
| JP5436941B2 (en) * | 2009-06-03 | 2014-03-05 | あすか製薬株式会社 | Lactam compound or salt thereof and PPAR activator |
| UY34200A (en) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3- (FLUOROVINIL) PIRAZOLES AND ITS USE |
| US10954272B2 (en) * | 2014-12-11 | 2021-03-23 | Centrient Pharmaceuticals Netherlands B.V. | Method for acylating a cyclic peptide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2320387A1 (en) * | 1973-04-21 | 1974-10-31 | Boehringer Mannheim Gmbh | PHENOXYALKYLCARBONIC ACID DERIVATIVES AND METHOD FOR PREPARING THE SAME |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-09-24 EE EEP200300140A patent/EE200300140A/en unknown
- 2001-09-24 WO PCT/EP2001/011005 patent/WO2002028821A2/en active IP Right Grant
- 2001-09-24 IL IL15512501A patent/IL155125A0/en unknown
- 2001-09-24 EP EP01974287A patent/EP1328508A2/en not_active Withdrawn
- 2001-09-24 SK SK413-2003A patent/SK4132003A3/en not_active Application Discontinuation
- 2001-09-24 JP JP2002532408A patent/JP2004510757A/en active Pending
- 2001-09-24 NZ NZ525119A patent/NZ525119A/en unknown
- 2001-09-24 HU HU0302306A patent/HUP0302306A3/en unknown
- 2001-09-24 MX MXPA03002901A patent/MXPA03002901A/en unknown
- 2001-09-24 AU AU2001293838A patent/AU2001293838A1/en not_active Abandoned
- 2001-09-24 BR BR0114437-5A patent/BR0114437A/en not_active IP Right Cessation
- 2001-09-24 CA CA002424540A patent/CA2424540A1/en not_active Abandoned
- 2001-09-24 CN CNA018200885A patent/CN1479716A/en active Pending
- 2001-09-24 RU RU2003112968/04A patent/RU2003112968A/en not_active Application Discontinuation
- 2001-09-24 PL PL01361162A patent/PL361162A1/en not_active Application Discontinuation
- 2001-09-24 CZ CZ2003964A patent/CZ2003964A3/en unknown
- 2001-10-03 UY UY26951A patent/UY26951A1/en not_active Application Discontinuation
- 2001-10-04 HN HN2001000223A patent/HN2001000223A/en unknown
-
2003
- 2003-03-28 BG BG107684A patent/BG107684A/en unknown
- 2003-04-03 NO NO20031517A patent/NO20031517L/en not_active Application Discontinuation
- 2003-04-04 MA MA27091A patent/MA25917A1/en unknown
- 2003-05-02 HR HR20030346A patent/HRP20030346A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BG107684A (en) | 2003-10-31 |
| MXPA03002901A (en) | 2003-10-15 |
| AU2001293838A1 (en) | 2002-04-15 |
| HN2001000223A (en) | 2001-10-25 |
| CA2424540A1 (en) | 2003-04-02 |
| HUP0302306A3 (en) | 2005-02-28 |
| WO2002028821A2 (en) | 2002-04-11 |
| CN1479716A (en) | 2004-03-03 |
| HRP20030346A2 (en) | 2005-04-30 |
| RU2003112968A (en) | 2004-09-20 |
| BR0114437A (en) | 2003-07-01 |
| SK4132003A3 (en) | 2004-02-03 |
| JP2004510757A (en) | 2004-04-08 |
| EP1328508A2 (en) | 2003-07-23 |
| PL361162A1 (en) | 2004-09-20 |
| UY26951A1 (en) | 2002-06-20 |
| IL155125A0 (en) | 2003-10-31 |
| CZ2003964A3 (en) | 2003-08-13 |
| EE200300140A (en) | 2003-08-15 |
| MA25917A1 (en) | 2003-10-01 |
| WO2002028821A3 (en) | 2002-08-15 |
| NO20031517L (en) | 2003-05-28 |
| NZ525119A (en) | 2005-04-29 |
| NO20031517D0 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302306A2 (en) | Propionic acid derivatives with ppar-alpha activating properties | |
| HUP0401192A2 (en) | Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds | |
| HUP0203971A2 (en) | Imidazoimidazoles and triazoles as anti-inflammatory agents and pharmaceutical compositions containing them and their use | |
| HUP0401339A2 (en) | Novel 4-anilinoquinoline-3-carboxamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0002347A2 (en) | Use of hydantoin, oxazole and pyrrole derivatives for the preparation of pharmaceutical compositions inflammatory disease treating | |
| HUP0500543A2 (en) | Pyridone derivatives as ap2 inhibitors and pharmaceutical compositions containing them | |
| WO2004055005A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
| HUP0402376A2 (en) | Imidazole-4-carboxamide derivatives, their preparation and pharmaceutical compositions suitable for treatment of obesity containing them | |
| JP2004517843A5 (en) | ||
| NO20051263L (en) | New use of benzothiazole derivatives | |
| HUP0303281A2 (en) | Benzodiazepine derivatives as gaba a receptor modulators, process for their preparation and pharmaceutical compositions containing them | |
| JP2007507494A5 (en) | ||
| HUP0400370A2 (en) | Antibacterial oxazolidinone-derivatives, process for their preparation, pharmaceutical compositions containing them, their use and intermediates | |
| HUP0201284A2 (en) | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient | |
| HUP0301458A2 (en) | Benzoxazinone derivatives, their preparation and use | |
| RU2007141887A (en) | PROTECTIVE AGENT FOR NEURAL RETAIL CELLS CONTAINING AS AN ACTIVE INGREDIENT INDOSOL DERIVATIVES | |
| ATE366107T1 (en) | USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE | |
| HUP0003577A2 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| RU2005129333A (en) | 4 - [(2,4-Dichloro-5-methoxyphenyl) amino] -6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic damage | |
| HUP0300295A2 (en) | Substituted benzamide derivatives, pharmaceutical compositions containing them and their use | |
| HUP0201282A2 (en) | Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient | |
| HUP0201287A2 (en) | Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient | |
| DE60202970D1 (en) | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| HUP0303612A2 (en) | Bicyclic guanidine derivatives and their therapeutic use | |
| RU2000131615A (en) | APPLICATION OF DERIVATIVES OF ARYL (OR HETEROARIL) AZOLYL CARBINOLS IN THE PRODUCTION OF A PREPARATION FOR THE TREATMENT OF NEUROGENOUS INFLAMMATION |